Compare MNTK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | SGHT |
|---|---|---|
| Founded | 1980 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.2M | 282.9M |
| IPO Year | 2020 | 2021 |
| Metric | MNTK | SGHT |
|---|---|---|
| Price | $1.35 | $3.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.33 | ★ $9.08 |
| AVG Volume (30 Days) | 209.6K | ★ 367.4K |
| Earning Date | 06-22-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $176,382,000.00 | $77,363,000.00 |
| Revenue This Year | $17.70 | $13.54 |
| Revenue Next Year | $16.52 | $14.53 |
| P/E Ratio | $141.00 | ★ N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $1.21 | $2.03 |
| 52 Week High | $2.78 | $9.24 |
| Indicator | MNTK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 29.02 |
| Support Level | N/A | $3.26 |
| Resistance Level | $1.79 | $3.76 |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 25.96 | 3.27 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.